Safety of Immunotherapy Rechallenge After Immune-related Adverse Events in Patients With Advanced Cancer
This retrospective study aimed to investigate the safety profile of continuing or rechallenging patients with advanced cancer who developed grade≥2 immune-related adverse events (irAEs) on immunotherapy-based regimens. Our study had 25, 20, and 40 patients (N=85) in the Treatment Continuation (TCG), Non-Rechallenge (NRG), and Rechallenge Groups (RG), respectively. Subsequent irAEs recurrence were more common in RG than TCG and NRG (78% vs. 56% vs. 25%, P<0.001). The same subsequent irAEs recurrences occurred on 42% of RG, 4% of TCG, and 15% of NRG (P<0.001). On the RG, there was a nonstatistical trend of shortening interval time between time from treatment rechallenge to subsequent irAEs when compared with time from first treatment to initial grade≥2 irAEs (5.86 vs. 8.86 wk, P=0.114). Patients who had cardiac irAEs were not rechallenged. Several high-risk features were identified to prognosticate risk of irAEs recurrences upon treatment rechallenge, including age 65 years and above (P=0.007), programmed cell death protein 1 inhibitors (P<0.001), grade 3 irAEs (P=0.003), pneumonitis type (P=0.048), any systemic corticosteroid use (P=0.001)/high-dose systemic corticosteroid use (P=0.007)/prolonged ≥4-week corticosteroid use (P=0.001) for irAEs management, and early development of irAEs (P=0.003). Our study concluded that it was relatively safe to continue or rechallenge patients with advanced cancers on immunotherapy-based regimens postdevelopment of certain grade≥2 irAEs, except for cardiac, neurological, or any grade 4 irAEs. Subsequent irAEs were common, no more severe, involved the same organ sites, and occurred more quickly than the original irAE. Close monitoring of all potential irAEs is required when rechallenging a patient on immunotherapy, especially for patients with high-risk features.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
---|---|
Enthalten in: |
Journal of immunotherapy (Hagerstown, Md. : 1997) - 44(2021), 1 vom: 01. Jan., Seite 41-48 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Kartolo, Adi [VerfasserIn] |
---|
Links: |
---|
Themen: |
Adrenal Cortex Hormones |
---|
Anmerkungen: |
Date Completed 26.11.2021 Date Revised 02.10.2023 published: Print Citation Status MEDLINE |
---|
doi: |
10.1097/CJI.0000000000000337 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM313897654 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM313897654 | ||
003 | DE-627 | ||
005 | 20231225151551.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1097/CJI.0000000000000337 |2 doi | |
028 | 5 | 2 | |a pubmed24n1046.xml |
035 | |a (DE-627)NLM313897654 | ||
035 | |a (NLM)32815895 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Kartolo, Adi |e verfasserin |4 aut | |
245 | 1 | 0 | |a Safety of Immunotherapy Rechallenge After Immune-related Adverse Events in Patients With Advanced Cancer |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 26.11.2021 | ||
500 | |a Date Revised 02.10.2023 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a This retrospective study aimed to investigate the safety profile of continuing or rechallenging patients with advanced cancer who developed grade≥2 immune-related adverse events (irAEs) on immunotherapy-based regimens. Our study had 25, 20, and 40 patients (N=85) in the Treatment Continuation (TCG), Non-Rechallenge (NRG), and Rechallenge Groups (RG), respectively. Subsequent irAEs recurrence were more common in RG than TCG and NRG (78% vs. 56% vs. 25%, P<0.001). The same subsequent irAEs recurrences occurred on 42% of RG, 4% of TCG, and 15% of NRG (P<0.001). On the RG, there was a nonstatistical trend of shortening interval time between time from treatment rechallenge to subsequent irAEs when compared with time from first treatment to initial grade≥2 irAEs (5.86 vs. 8.86 wk, P=0.114). Patients who had cardiac irAEs were not rechallenged. Several high-risk features were identified to prognosticate risk of irAEs recurrences upon treatment rechallenge, including age 65 years and above (P=0.007), programmed cell death protein 1 inhibitors (P<0.001), grade 3 irAEs (P=0.003), pneumonitis type (P=0.048), any systemic corticosteroid use (P=0.001)/high-dose systemic corticosteroid use (P=0.007)/prolonged ≥4-week corticosteroid use (P=0.001) for irAEs management, and early development of irAEs (P=0.003). Our study concluded that it was relatively safe to continue or rechallenge patients with advanced cancers on immunotherapy-based regimens postdevelopment of certain grade≥2 irAEs, except for cardiac, neurological, or any grade 4 irAEs. Subsequent irAEs were common, no more severe, involved the same organ sites, and occurred more quickly than the original irAE. Close monitoring of all potential irAEs is required when rechallenging a patient on immunotherapy, especially for patients with high-risk features | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
700 | 1 | |a Holstead, Ryan |e verfasserin |4 aut | |
700 | 1 | |a Khalid, Sidra |e verfasserin |4 aut | |
700 | 1 | |a Emack, Jeffrey |e verfasserin |4 aut | |
700 | 1 | |a Hopman, Wilma |e verfasserin |4 aut | |
700 | 1 | |a Baetz, Tara |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of immunotherapy (Hagerstown, Md. : 1997) |d 1998 |g 44(2021), 1 vom: 01. Jan., Seite 41-48 |w (DE-627)NLM090458141 |x 1537-4513 |7 nnns |
773 | 1 | 8 | |g volume:44 |g year:2021 |g number:1 |g day:01 |g month:01 |g pages:41-48 |
856 | 4 | 0 | |u http://dx.doi.org/10.1097/CJI.0000000000000337 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 44 |j 2021 |e 1 |b 01 |c 01 |h 41-48 |